Telix Pharmaceuticals (TLX1N) Stock Price & Analysis
TLX1N Stock Chart & Stats
- Day’s Range
- MXN 302.55 - MXN 302.55
- 52-Week Range
- MXN 302.55 - MXN 302.55
- Previous Close
- MXN 302.55
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 59.00B
- Enterprise Value
- MXN 6.39B
- Total Cash (Recent Filing)
- MXN 251.80M
- Total Debt (Recent Filing)
- MXN 579.61M
- Price to Earnings (P/E)
- 96.6
- Beta
- -0.80
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- 1.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Commercial Growth
Sustained double-digit growth across the group and core Precision Medicine franchise indicates expanding commercial adoption rather than reliance on a single temporary gain. Continued growth at this scale can strengthen operating leverage, support pipeline investment, and broaden Telix’s revenue base over the next several quarters.
Healthy And Improving Margins
Improving gross margins alongside disciplined operating expenses points to better product economics and operating leverage as revenue scales. This supports more durable profitability potential, gives management greater capacity to fund development internally, and reduces the amount of incremental revenue needed to support future earnings.
Broader Platform And Infrastructure
Adding an approved product in neuro-oncology while pursuing a vertically integrated ITM combination could diversify revenue and expand therapeutic reach. Broader isotope production, manufacturing, and pipeline capabilities may improve Telix’s ability to serve patients at scale and support multiple future launches.
Bears Say
Recent Cash-flow Reversal
The reversal into negative operating and free cash flow weakens cash conversion and increases reliance on financing while the company continues investing in growth. If sustained, it could constrain reinvestment flexibility and make execution more sensitive to spending levels, working capital needs, and product timing.
Rising Leverage
Debt growing faster than the equity base reduces financial flexibility for a business with volatile earnings and substantial development investment. Elevated leverage can increase interest and refinancing exposure, limit capacity for additional strategic spending, and amplify the consequences if profitability softens.
Zircaix Regulatory Hurdle
The FDA response delays potential commercialization of an important pipeline asset and leaves approval timing dependent on addressing identified manufacturing deficiencies. A prolonged resubmission process could defer revenue diversification, increase regulatory execution costs, and keep future growth dependent on existing products.
Telix Pharmaceuticals News
TLX1N FAQ
What was Telix Pharmaceuticals’s price range in the past 12 months?
What is Telix Pharmaceuticals’s market cap?
When is Telix Pharmaceuticals’s upcoming earnings report date?
How were Telix Pharmaceuticals’s earnings last quarter?
Is Telix Pharmaceuticals overvalued?
Does Telix Pharmaceuticals pay dividends?
What is Telix Pharmaceuticals’s EPS estimate?
How many shares outstanding does Telix Pharmaceuticals have?
What happened to Telix Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Telix Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Telix Pharmaceuticals Stock Smart Score
Company Description
Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christian Behrenbruch
- Employees
- 1,152
- Website
- telixpharma.com
- Address
- 55 Flemington Road, North Melbourne, VIC, 3051, AU
Telix Pharmaceuticals (TLX1N) Earnings & Revenues
TLX1N Company Deck
TLX1N Earnings Call
Earnings Call SentimentPositive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.
View all MX:TLX1N earnings summariesTLX1N Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 7 |
| Technical Analysis | 0 | 1 | 1 |
| Moving Averages | 4 | 2 | 6 |
